Compare Quest Diagnostics Inc (DGX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Spotify Technology — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Spotify Technology trades at $529.14 (market cap $108.22B). The key difference: Spotify Technology is far larger — about 4.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Spotify Technology for 111 Days on average.
| DGX | SPOT | |
|---|---|---|
Market Cap | $25.48B | $108.22B |
Volume | 941,866 | 1,655,796 |
Sector | Health | Media |
52-Week High | $247.45 | $692.04 |
52-Week Low | $173.49 | $412.75 |
Typical Hold Time | 56 Days | 111 Days |
Enterprise Value | $31.23B | $98.23B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Spotify (SPOT) trades at $526.42, up 2.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamental improvement with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains overwhelmingly positive with 62% buy ratings and a $606.50 consensus target.
The outlook remains favorable with expanding gross margins and positive cash flow trends, though competition and market volatility present risks. With strong institutional support and upcoming Q3 earnings on October 22, 2026, SPOT offers growth potential but requires monitoring of execution against elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
